Anthem Biosciences confirms no encumbrance on promoter shares in FY26

1 min read     Updated on 09 Jul 2026, 05:32 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Anthem Biosciences confirmed via a regulatory filing that its promoter group, led by Ishaan Bhardwaj, did not encumber any shares during FY26. The disclosure, submitted to BSE and NSE under SEBI takeover regulations, listed eight promoter group members, including foreign nationals, and confirmed compliance with required transparency norms.

powered bylight_fuzz_icon
45100926

*this image is generated using AI for illustrative purposes only.

Anthem Biosciences has confirmed that its promoter group did not pledge or encumber any shares during the financial year ended March 31, 2026. This disclosure ensures that the shareholding structure remains free of liens or charges, which is critical for maintaining shareholder confidence and regulatory compliance. The declaration was submitted to BSE and NSE on April 10, 2026, by Ishaan Bhardwaj on behalf of the promoter and promoter group.

The filing was made pursuant to Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations require promoters to disclose any encumbrance over shares held directly or indirectly. The confirmation from the promoter group indicates that no such financial arrangements were established involving the company's equity during the specified period.

Promoter Group Details

The disclosure identified the members of the promoter group, including Ishaan Bhardwaj and seven other individuals. The list was provided as Annexure A to the regulatory filing. The group consists of both Indian residents and foreign nationals, with specific details regarding their Permanent Account Numbers (PAN) where applicable.

Name of the Promoter and Promoter Group PAN
Ishaan Bhardwaj
Kashmira Nayar
Madhavi Jayanti
Ajay Bhardwaj
Arti Bhardwaj
Raman Nayar Not Applicable (Foreign National)
Pramila Raman Nayar Not Applicable (Foreign National)
Nischel Rye Nayar Not Applicable (Foreign National)
Rahul Vyan Nayar Not Applicable (Foreign National)

The company requested that the exchanges place this information on record. A copy of the declaration was also forwarded to the Audit Committee of Anthem Biosciences Limited for its information and records.

Historical Stock Returns for Anthem Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.47%-1.45%-2.73%+16.59%+2.96%+2.96%

How might the absence of share encumbrances influence Anthem Biosciences' ability to secure future financing for expansion?

What impact will this clean shareholding structure have on investor confidence and stock volatility in the upcoming quarter?

Could the promoter group's current financial stability signal potential strategic acquisitions or partnerships in the near future?

Anthem Biosciences sets AGM for July 22 to approve ₹2 dividend

1 min read     Updated on 01 Jul 2026, 06:05 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Anthem Biosciences Limited has announced its 20th Annual General Meeting for July 22, 2026, to be held virtually. The primary agenda includes the approval of a final dividend of ₹2 per equity share for the financial year ended March 31, 2026. Shareholders of record as of June 26, 2026, will be eligible for the dividend, which is to be paid by August 21, 2026. The meeting will also address the appointment of statutory auditors, remuneration for independent directors and related parties, and an upside sharing arrangement with Viridity Tone LLP.

powered bylight_fuzz_icon
44271959

*this image is generated using AI for illustrative purposes only.

Anthem Biosciences Limited has scheduled its 20th Annual General Meeting (AGM) for Wednesday, July 22, 2026, at 3:30 p.m. IST through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The meeting seeks shareholder approval for a final dividend of ₹2 per equity share for the financial year ended March 31, 2026. The record date for determining shareholder eligibility is Friday, June 26, 2026, and the dividend is scheduled to be paid on or before Friday, August 21, 2026, subject to approval at the AGM.

The Board of Directors recommended the dividend at a meeting held on May 19, 2026. The company has appointed KFin Technologies Limited as the Registrar and Share Transfer Agent to facilitate the virtual meeting and e-voting processes. Remote e-voting will be available from July 19, 2026, at 9:00 a.m. IST to July 21, 2026, at 5:00 p.m. IST, with a cut-off date of July 17, 2026, for determining eligibility.

Key AGM and Dividend Details

Event Date/Time
AGM Date July 22, 2026, at 3:30 p.m. IST
Record Date for Dividend June 26, 2026
Dividend Payment Date On or before August 21, 2026
Remote E-voting Start July 19, 2026, at 9:00 a.m. IST
Remote E-voting End July 21, 2026, at 5:00 p.m. IST
Cut-off Date for E-voting July 17, 2026

The notice also includes resolutions for the appointment of M/s. S.R. Batliboi & Associates LLP as Statutory Auditors for a term of five years, remuneration for Independent Directors, and the approval of remuneration for specified related party employees. Additionally, shareholders will vote on an Upside Sharing Arrangement with Viridity Tone LLP. The company noted that dividends are taxable in the hands of shareholders, and Tax Deducted at Source (TDS) will be applicable as per prescribed rates.

Historical Stock Returns for Anthem Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.47%-1.45%-2.73%+16.59%+2.96%+2.96%

What strategic benefits does the Upside Sharing Arrangement with Viridity Tone LLP offer Anthem Biosciences?

How will the appointment of M/s. S.R. Batliboi & Associates LLP impact the company's financial governance over the next five years?

Will the ₹2 per share dividend payout impact Anthem Biosciences' capital allocation plans for the upcoming fiscal year?

More News on Anthem Biosciences

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+2.96%